CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has regained compliance with Nasdaq's equity requirement. The company received notice from Nasdaq on September 10, 2024, confirming its compliance with Listing Rule 5550(b)(1). This development is subject to a one-year Nasdaq Mandatory Panel Monitor related to the equity requirement. With this compliance issue resolved, Nasdaq has informed CNS Pharmaceuticals that the matter is now closed.
CNS Pharmaceuticals (NASDAQ:CNSP), un'azienda biofarmaceutica focalizzata nello sviluppo di nuovi trattamenti per i tumori cerebrali e del sistema nervoso centrale, ha recuperato la conformità con il requisito patrimoniale di Nasdaq. L'azienda ha ricevuto notifica da Nasdaq il 10 settembre 2024, confermando la sua conformità con la Regola di Listing 5550(b)(1). Questo sviluppo è soggetto a un monitoraggio obbligatorio del pannello Nasdaq della durata di un anno relativo al requisito patrimoniale. Risolto questo problema di conformità, Nasdaq ha informato CNS Pharmaceuticals che la questione è ora chiusa.
CNS Pharmaceuticals (NASDAQ:CNSP), una compañía biofarmacéutica enfocada en desarrollar tratamientos novedosos para los cánceres del cerebro y del sistema nervioso central, ha recuperado el cumplimiento con el requisito patrimonial de Nasdaq. La compañía recibió notificación de Nasdaq el 10 de septiembre de 2024, confirmando su cumplimiento con la Regla de Listado 5550(b)(1). Este desarrollo está sujeto a un monitoreo obligatorio del panel de Nasdaq relacionado con el requisito patrimonial durante un año. Con este problema de cumplimiento resuelto, Nasdaq ha informado a CNS Pharmaceuticals que el asunto está ahora cerrado.
CNS Pharmaceuticals (NASDAQ:CNSP)는 뇌 및 중추신경계 암을 위한 새로운 치료법 개발에 주력하는 바이오 제약 회사로, 나스닥의 자본 요건을 다시 충족하게 되었습니다. 이 회사는 2024년 9월 10일 나스닥으로부터 5550(b)(1) 상장 규정 준수에 대한 확인 통지를 받았습니다. 이 발전은 자본 요건과 관련하여 1년간의 나스닥 의무 패널 모니터링을 받게 됩니다. 이 문제의 준수가 해결됨에 따라, 나스닥은 CNS Pharmaceuticals에 이 문제가 이제 종료되었다고 통보했습니다.
CNS Pharmaceuticals (NASDAQ:CNSP), une entreprise biopharmaceutique axée sur le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a récupéré sa conformité aux exigences de fonds propres de Nasdaq. L'entreprise a reçu une notification de Nasdaq le 10 septembre 2024, confirmant sa conformité à la règle de cotation 5550(b)(1). Ce développement est soumis à un suivi obligatoire par un panel de Nasdaq d'une durée d'un an concernant l'exigence de fonds propres. Avec ce problème de conformité résolu, Nasdaq a informé CNS Pharmaceuticals que l'affaire est maintenant close.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Behandlungen für Hirn- und zentrale Nervensystemtumoren konzentriert, hat die Einhaltung der Eigenkapitalanforderung von Nasdaq zurückerlangt. Das Unternehmen erhielt am 10. September 2024 eine Mitteilung von Nasdaq, die die Einhaltung der Listing-Regel 5550(b)(1) bestätigte. Diese Entwicklung unterliegt einer einjährigen obligatorischen Überwachung durch ein Nasdaq-Panel in Bezug auf die Eigenkapitalanforderung. Nachdem dieses Compliance-Problem gelöst wurde, hat Nasdaq CNS Pharmaceuticals informiert, dass die Angelegenheit nun abgeschlossen ist.
- Regained compliance with Nasdaq's equity requirement
- Matter closed by Nasdaq, reducing regulatory concerns
- Subject to one-year Nasdaq Mandatory Panel Monitor for equity requirement
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on September 10, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the equity requirement under Nasdaq's Listing Rule 5550(b)(1), subject to Nasdaq Mandatory Panel Monitor related to the equity requirement for a period of one year. Now that the Company has regained compliance with Listing Rule 5550(b)(1), Nasdaq has advised the Company that this matter is now closed.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What did CNS Pharmaceuticals (CNSP) announce on September 12, 2024?
Is CNS Pharmaceuticals (CNSP) still at risk of Nasdaq delisting?
What is CNS Pharmaceuticals' (CNSP) main business focus?
When did CNS Pharmaceuticals (CNSP) receive the compliance notice from Nasdaq?
